Potent and biostable inhibitors of the main protease of SARS-CoV-2

[1]  Hao Tan,et al.  Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir , 2022, bioRxiv.

[2]  B. Sankaran,et al.  A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals , 2022, European Journal of Medicinal Chemistry.

[3]  Kai S Yang,et al.  Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir , 2022, Journal of medicinal chemistry.

[4]  Xinwen Chen,et al.  The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate , 2022, European Journal of Medicinal Chemistry.

[5]  Y. Orba,et al.  Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 , 2022, Journal of medicinal chemistry.

[6]  Hao Tan,et al.  Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity , 2021, Journal of the American Chemical Society.

[7]  G. Otting,et al.  Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir , 2021, bioRxiv.

[8]  T. Itoh,et al.  Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19 , 2021, ACS central science.

[9]  K. Gajiwala,et al.  An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.

[10]  C. Müller,et al.  3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. , 2021, Journal of medicinal chemistry.

[11]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[12]  Taylor M. Barrett,et al.  Rational design of thioamide peptides as selective inhibitors of cysteine protease cathepsin L , 2021, Chemical science.

[13]  J. Vederas,et al.  Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability , 2021, Journal of medicinal chemistry.

[14]  Chunlong Ma,et al.  Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir , 2021, ACS pharmacology & translational science.

[15]  Yuquan Wei,et al.  SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model , 2021, Science.

[16]  Arun K. Ghosh,et al.  A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication , 2021, Nature Communications.

[17]  D. Venzon,et al.  Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. , 2020, Journal of hepatology.

[18]  R. Likić,et al.  Will vaccination refusal prolong the war on SARS-CoV-2? , 2020, Postgraduate Medical Journal.

[19]  K. Gajiwala,et al.  Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 , 2020, Journal of medicinal chemistry.

[20]  Arun K. Ghosh,et al.  Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity , 2020, Scientific Reports.

[21]  Joe Pardo,et al.  The journey of remdesivir: from Ebola to COVID-19 , 2020, Drugs in context.

[22]  R. D’Aquila,et al.  Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs , 2020 .

[23]  H. Mitsuya,et al.  Sustaining containment of COVID-19: global sharing for pandemic response. , 2020, Global health & medicine.

[24]  Edward Livingston,et al.  Coronavirus Disease 2019 (COVID-19) in Italy. , 2020, JAMA.

[25]  Fumihiro Kato,et al.  Development of Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan. , 2020, Japanese journal of infectious diseases.

[26]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[27]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[28]  Taylor M. Barrett,et al.  Fluorescent Probes for Studying Thioamide Positional Effects on Proteolysis Reveal Insight into Resistance to Cysteine Proteases , 2019, Chembiochem : a European journal of chemical biology.

[29]  Arun K. Ghosh,et al.  Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants , 2019, Antimicrobial Agents and Chemotherapy.

[30]  Kunio Hirata,et al.  ZOO: an automatic data-collection system for high-throughput structure analysis in protein microcrystallography , 2019, Acta crystallographica. Section D, Structural biology.

[31]  Arun K. Ghosh,et al.  Design of Highly Potent, Dual‐Acting and Central‐Nervous‐System‐Penetrating HIV‐1 Protease Inhibitors with Excellent Potency against Multidrug‐Resistant HIV‐1 Variants , 2018, ChemMedChem.

[32]  N. Meanwell.  Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. , 2018, Journal of medicinal chemistry.

[33]  Gwyndaf Evans,et al.  DIALS: implementation and evaluation of a new integration package , 2018, Acta crystallographica. Section D, Structural biology.

[34]  Taylor M. Barrett,et al.  Thioamide Substitution Selectively Modulates Proteolysis and Receptor Activity of Therapeutic Peptide Hormones. , 2017, Journal of the American Chemical Society.

[35]  F. Diederich,et al.  Fluorine Scan of Inhibitors of the Cysteine Protease Human Cathepsin L: Dipolar and Quadrupolar Effects in the π‐Stacking of Fluorinated Phenyl Rings on Peptide Amide Bonds , 2016, ChemMedChem.

[36]  M. D. Hill,et al.  Applications of Fluorine in Medicinal Chemistry. , 2015, Journal of medicinal chemistry.

[37]  R. Hilgenfeld.  From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design , 2014, The FEBS journal.

[38]  Noriyuki Furuichi,et al.  Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties. , 2013, ACS medicinal chemistry letters.

[39]  E. Freire,et al.  Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies , 2013, European Journal of Medicinal Chemistry.

[40]  S. Yokoyama,et al.  Autoprocessing mechanism of severe acute respiratory syndrome coronavirus 3C‐like protease (SARS‐CoV 3CL pro) from its polyproteins , 2013, The FEBS journal.

[41]  E. Freire,et al.  Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety , 2012, Bioorganic & Medicinal Chemistry.

[42]  Thomas Jaki,et al.  Estimation of pharmacokinetic parameters with the R package PK , 2011 .

[43]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[44]  Y. Liu,et al.  Maturation Mechanism of Severe Acute Respiratory Syndrome (SARS) Coronavirus 3C-like Proteinase , 2010, The Journal of Biological Chemistry.

[45]  Peng Zhou,et al.  Fluorine Bonding - How Does It Work In Protein-Ligand Interactions? , 2009, J. Chem. Inf. Model..

[46]  F. Diederich,et al.  A fluorine scan of non-peptidic inhibitors of neprilysin: Fluorophobic and fluorophilic regions in an enzyme active site , 2008 .

[47]  Arun K. Ghosh,et al.  Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors , 2007, Bioorganic & Medicinal Chemistry Letters.

[48]  Andrew D Westwell,et al.  The role of fluorine in medicinal chemistry , 2007, Journal of enzyme inhibition and medicinal chemistry.

[49]  Manfred Kansy,et al.  A Fluorine Scan at the Catalytic Center of Thrombin: CF, COH, and COMe Bioisosterism and Fluorine Effects on pKa and log D Values , 2006, ChemMedChem.

[50]  Zhongbin Chen,et al.  The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Activity , 2005, Journal of Virology.

[51]  R. Ménard,et al.  The Papain-Like Protease from the Severe Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating Enzyme , 2005, Journal of Virology.

[52]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[53]  B. Smart.  Fluorine substituent effects (on bioactivity) , 2001 .

[54]  D. Matthews,et al.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. , 1999, Journal of medicinal chemistry.

[55]  H. Rapoport,et al.  Thiopeptide Synthesis. α-Amino Thionoacid Derivatives of Nitrobenzotriazole as Thioacylating Agents. , 1997 .

[56]  H. Rapoport,et al.  Thiopeptide Synthesis. alpha-Amino Thionoacid Derivatives of Nitrobenzotriazole as Thioacylating Agents. , 1996, The Journal of organic chemistry.

[57]  R. Allison,et al.  THE USE OF ETHIONAMIDE IN COMBINED DRUG REGIMENS IN THE RE-TREATMENT OF ISONIAZID-RESISTANT PULMONARY TUBERCULOSIS. , 1965, The American review of respiratory disease.

[58]  Yuquan Wei,et al.  SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model , 2021 .

[59]  Alexei Vagin,et al.  Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.